Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Accumulated Depreciation (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Accumulated Depreciation for 4 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation rose 25.17% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, up 25.17% year-over-year, with the annual reading at $1.6 million for FY2025, 25.17% up from the prior year.
  • Accumulated Depreciation for Q4 2025 was $1.6 million at Orchestra BioMed Holdings, up from $1.5 million in the prior quarter.
  • The five-year high for Accumulated Depreciation was $1.6 million in Q4 2025, with the low at $778000.0 in Q4 2022.
  • Average Accumulated Depreciation over 4 years is $1.2 million, with a median of $1.2 million recorded in 2024.
  • The sharpest move saw Accumulated Depreciation surged 34.19% in 2023, then rose 22.76% in 2024.
  • Over 4 years, Accumulated Depreciation stood at $778000.0 in 2022, then soared by 34.19% to $1.0 million in 2023, then grew by 24.81% to $1.3 million in 2024, then rose by 25.17% to $1.6 million in 2025.
  • According to Business Quant data, Accumulated Depreciation over the past three periods came in at $1.6 million, $1.5 million, and $1.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.